Parallax Volatility Advisers
AKTX

Parallax Volatility Advisers’s Akari Therapeutics AKTX Stock Holding History

Parallax Volatility Advisers’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9
Closed -$15K – 2272
2019
Q2 		$15K Hold
9
– – ﹤0.01% 2117
2019
Q1 		$27K Hold
9
– – ﹤0.01% 2469
2018
Q4 		$12K Hold
9
– – ﹤0.01% 2474
2018
Q3 		$19K Hold
9
– – ﹤0.01% 2143
2018
Q2 		$15K Hold
9
– – ﹤0.01% 1703
2018
Q1 		$14K Hold
9
– – ﹤0.01% 1764
2017
Q4 		$32K Buy
+9
New +$34.7K ﹤0.01% 3455

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parallax Volatility Advisers's AKTX Position: Q3 2019 in Review

Parallax Volatility Advisers sold out of Akari Therapeutics (AKTX) in Q3 2019, closing a stake of 9 shares — an estimated $15K sold.

Parallax Volatility Advisers first reported a position in AKTX in Q4 2017 and held it in 7 quarters. The position peaked at $32K in Q4 2017. 10 funds tracked by Wall St. Rank hold AKTX as of Q3 2019.

  • Parallax Volatility Advisers reported no remaining Akari Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 9 Akari Therapeutics shares in Q3 2019, an estimated $15K.
  • Parallax Volatility Advisers first reported a position in Akari Therapeutics in Q4 2017 and held it in 7 quarters.
  • Parallax Volatility Advisers's Akari Therapeutics position peaked at $32K in Q4 2017.
  • 10 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2019.

Based on Parallax Volatility Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.